<SEC-DOCUMENT>0001157523-16-005580.txt : 20160512
<SEC-HEADER>0001157523-16-005580.hdr.sgml : 20160512
<ACCEPTANCE-DATETIME>20160511175539
ACCESSION NUMBER:		0001157523-16-005580
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160511
FILED AS OF DATE:		20160512
DATE AS OF CHANGE:		20160511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		161641048

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51340796.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font>
    </p>
    <hr style="text-align: center; height: 1.0 pt; width: 100%; color: #000000">


    <p style="text-align: center">
      <font style="font-size: 14pt; font-family: Times New Roman"><b>FORM 6-K</b></font>
    </p>
    <hr style="text-align: center; height: 1.0 pt; width: 100%; color: #000000">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-size: 12pt; font-family: Times New Roman">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-size: 12pt; font-family: Times New Roman"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Dated</b></font><font style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>May
      11, 2016</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="text-align: center; height: 1.0 pt; width: 100%; color: #000000">


    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b><br>
    </p>
    <hr style="text-align: center; height: 1.0 pt; width: 100%; color: #000000">


    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principle executive offices)</b>
    </p>
    <hr style="text-align: center; height: 1.0 pt; width: 100%; color: #000000">


    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F:</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Form 20-F &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font>
    </p>
    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Yes &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: Times New Roman">
      No &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font>
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">If &quot;Yes&quot; is
      marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): Not a</font>pplicable.
    </p>
    <p style="text-align: justify; text-indent: 30.0px">

    </p>
    <div style="text-indent: 0pt; margin-right: 0pt; width: 100%; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized. </font>
    </p>
    <p style="text-indent: 30.0px">

    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: left; width: 6%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Dated:
          </p>
        </td>
        <td style="text-align: left; width: 44%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            May 11, 2016
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" valign="top" colspan="3">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="text-align: center; padding-left: 0.0px" valign="top" colspan="3">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-bottom: 2.0px; text-align: left; width: 6%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-bottom: 2.0px; text-align: left; width: 44%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-bottom: 2.0px; text-align: left; width: 3%; padding-left: 0.0px" valign="top">
          By:
        </td>
        <td style="text-align: left; border-bottom-style: solid; border-bottom-color: black; border-bottom-width: 1.0pt; padding-left: 0.0px" valign="top" colspan="2">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Dennis Bourgeault
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="text-align: left; width: 3%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; width: 5%; padding-left: 0.0px" valign="top">
          Name:
        </td>
        <td style="text-align: left; width: 42%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Dennis Bourgeault
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: left; width: 6%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; width: 44%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td style="text-align: left; width: 5%; padding-left: 0.0px" valign="top">
          Title:
        </td>
        <td style="text-align: left; width: 42%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; width: 100%; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center; font-size: 10pt; font-family: Times New Roman">
          2
        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
    <p style="text-align: center">

    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: left; border-bottom-style: solid; border-bottom-color: black; width: 8%; border-bottom-width: 1.0pt; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td style="padding-bottom: 2.0px; text-align: left; width: 5%; padding-left: 0.0px" valign="bottom">
          &#160;
        </td>
        <td style="text-align: left; border-bottom-style: solid; border-bottom-color: black; width: 87%; border-bottom-width: 1.0pt; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 8%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; width: 87%; padding-left: 0.0px" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; width: 8%; padding-left: 0.0px" valign="top">
          99.1
        </td>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; width: 87%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            News Release &#8211; Aurinia Reports First Quarter 2016 Financial
            Results and Operational Highlights
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>
      <br>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51340796_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Aurinia
      Reports First Quarter 2016 Financial Results and Operational Highlights</b></font>
    </p>
    <p style="text-align: left">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Enrollment
      completed in Phase 2b clinical trial with data read out in third quarter
      of 2016</b></font></i>
    </p>
    <p style="text-align: left">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>FDA
      Fast Track designation granted to voclosporin for lupus nephritis</b></font></i>
    </p>
    <p style="text-align: left">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Early
      AURION results support the use of voclosporin as a component of
      multi-targeted therapy in lupus nephritis</b></font></i>
    </p>
    <p style="text-align: left">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Company
      leadership team strengthened with expanded capabilities</b></font></i>
    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--May 11, 2016--Aurinia
      Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) (&#8220;Aurinia&#8221; or the &#8220;Company&#8221;)
      has released its financial results for the first quarter ended March 31,
      2016. Amounts, unless specified otherwise, are expressed in U.S. dollars.
    </p>
    <p style="text-align: left">
      The first quarter of 2016 was highlighted by the completion of patient
      enrollment in our Phase 2b (AURA) clinical trial and obtaining fast
      track designation from the FDA for voclosporin. In addition to these
      clinical and regulatory successes, the Company received promising data
      from the open-label AURION study that further supports our hypothesis on
      the potential for multi-targeted therapy with voclosporin for the
      treatment of lupus nephritis (LN). The team is focused on preparations
      for the AURA primary end point data release in the latter half of the
      third quarter of 2016 and initiation of the Phase 3 program in 2017. The
      Company is making the necessary investments now to ensure the team has
      the tools to deliver future success. The remainder of the year will also
      see further data releases from the AURION study including some 24 and 48
      week data points.
    </p>
    <p style="text-align: left">
      The Company will also be completing assessments of key markets in the
      Americas, Europe and Asia. The Company will share more on these
      developments during future investor presentations.
    </p>
    <p style="text-align: left">
      &#8220;While only being in this role a short time, I am both excited and
      greatly encouraged by the performance and focus of the team. I plan to
      continue to execute on initiatives to maximize shareholder value and
      help bring a desperately needed therapy to market for patients suffering
      from LN.&#8221; said Charlie Rowland, CEO of Aurinia Pharmaceuticals Inc.
    </p>
    <p style="text-align: left">
      <b>Key Developments</b>
    </p>
    <p style="text-align: left">
      <b>AURA Phase 2b Clinical Trial Update &#8211; Patient Enrollment Completed</b>
    </p>
    <p style="text-align: left">
      On January 19, 2016, the Company announced completion of patient
      enrollment of its AURA clinical trial at 265 patients. This Phase 2b
      trial, is a randomized, controlled, double-blind study comparing the
      efficacy of voclosporin as a component of multi-targeted therapy against
      placebo in achieving remission in patients with active lupus nephritis
      (LN). AURA is one of the largest prospective registration-quality
      studies ever conducted within this specific disease area.
    </p>
    <div style="text-indent: 0pt; margin-right: 0pt; width: 100%; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: left">
      <b>FDA Fast Track</b>
    </p>
    <p style="text-align: left">
      On March 2, 2016 the Company announced that the U.S. Food and Drug
      Administration (FDA) granted Fast Track designation for voclosporin, the
      Company&#8217;s next generation calcineurin inhibitor, for the treatment of LN.
    </p>
    <p style="text-align: left">
      The Fast Track program was created by the FDA to facilitate the
      development and expedite the review of new drugs that are intended to
      treat serious or life-threatening conditions and that demonstrate the
      potential to address significant unmet medical needs. Compounds that
      receive this FDA designation benefit from more frequent meetings and
      communications with the FDA to review the drug&#8217;s development plan
      including the design of clinical trials and the use of biomarkers to
      support approval. Additionally, Fast Track designation allows the
      Company to submit parts of the New Drug Application (NDA) on a rolling
      basis for review as data becomes available. The Company expects to
      analyse and review the AURA data with the FDA later in 2016 in order to
      determine the appropriate next steps.
    </p>
    <p style="text-align: left">
      <b>AURION Study Update</b>
    </p>
    <p style="text-align: left">
      On February 8, 2016 the Company announced that it had completed a
      preliminary analysis of its AURION (<u>A</u>urinia early <u>U</u>rinary
      protein <u>R</u>educt<u>ion</u> Predicts Response) study. In the first
      seven patients, of the 10 patients enrolled in the study, that have
      reached at least eight weeks of therapy in the AURION study, 100% (7/7)
      achieved at least a 25% reduction in proteinuria compared to study
      entry. A 25% reduction in proteinuria at eight weeks has been shown to
      be predictive of a positive clinical response at 24<sup> </sup>weeks<sup>1</sup>.
      Additionally, in the first eight weeks of the open-label AURION study an
      overall mean reduction of proteinuria of 72% compared to pre-treatment
      levels was observed, and 57% (4/7) of these patients achieved complete
      remission as defined by a urinary protein creatinine ratio of &#8804;
      0.5mg/mg. Overall renal function as measured by eGFR in these patients
      also remained stable. The Company plans to release further AURION data
      as it becomes available.
    </p>
    <p style="text-align: left">
      <b>Strengthening Leadership and Capabilities</b>
    </p>
    <p style="text-align: left">
      On April 11, 2016 the Company appointed Mr. Charles A. Rowland, Jr.,
      MBA, CPA, as its Chief Executive Officer. Mr. Rowland has more than 30
      years of experience&#160;in pharmaceutical operations, strategic value
      creation as well as financial management. He served as the Vice
      President and Chief Financial Officer of ViroPharma Incorporated, an
      international biopharmaceutical company, until it was acquired by Shire
      plc for $4.2B in January 2014. As a member of the executive team, he was
      key to developing the global strategic direction of the company, its
      international expansion&#160;and its strong financial position.
    </p>
    <p style="text-align: left">
      On April 29, 2016 the Company appointed Bradley J. Dickerson as an
      officer of the Company in the position of General Manager of the
      Americas and Global Commercial Assessment. Mr. Dickerson has more than
      15 years of experience in the healthcare industry with a focus on
      pharmaceutical market access, distribution and patient services. He
      served as Vice President, Access and Reimbursement at NPS
      Pharmaceuticals, until it was acquired by Shire plc. Prior to his role
      at NPS, Mr. Dickerson was Director of Managed Markets at ViroPharma with
      responsibility for all market access functions. He also provided
      leadership for the launch and ongoing commercialization of Cinryze&#174;.
    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; width: 100%; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: left">
      <b>Expected Upcoming Milestones and Events</b>
    </p>
    <ul style="text-align: left">
      <li style="margin-bottom: 10.0px">
        AURION 10 patients to 8 weeks &#8211; Q2/2016
      </li>
      <li style="margin-bottom: 10.0px">
        AURION 7 patients to 24 weeks &#8211; Q2/2016
      </li>
      <li style="margin-bottom: 10.0px">
        AURA-LV 24 week primary end-point data release &#8211; Q3/2016
      </li>
      <li style="margin-bottom: 10.0px">
        AURION 10 patients to 24 weeks &#8211; Q3/2016
      </li>
      <li style="margin-bottom: 10.0px">
        Filing for Breakthrough Designation &#8211; Q3/2016-pending data from AURA
        trial &#8211; 24 week results
      </li>
      <li style="margin-bottom: 10.0px">
        Investor Day-Fall/2016
      </li>
      <li style="margin-bottom: 10.0px">
        End of Phase 2 meeting with FDA &#8211; Q4/2016
      </li>
      <li style="margin-bottom: 10.0px">
        Scientific meetings:

        <ul>
          <li style="margin-bottom: 10.0px">
            Abstract presentation &#8211; European Renal Association / European
            Dialysis and Transplantation Meeting (ERA/EDTA) &#8211;Q2/2016
          </li>
          <li style="margin-bottom: 10.0px">
            Poster presentation &#8211; European League Against Rheumatism (EULAR) &#8211;
            Q2/2016
          </li>
        </ul>
      </li>
    </ul>
    <p style="text-align: left">
      <b>Financial Results for the First Quarter Ended March 31, 2016</b>
    </p>
    <p style="text-align: left">
      For the first quarter ended March 31, 2016, the Company reported a
      consolidated net loss of $4.3 million or $0.13 per common share, as
      compared to a consolidated net loss of $8.6 million or $0.27 per common
      share for the same period in 2015.
    </p>
    <p style="text-align: left">
      The decrease in the net loss was primarily attributable to recording a
      non-cash gain on revaluation of derivative warrant liability of $664,000
      in 2016 compared to a non-cash loss on revaluation of derivative warrant
      liability of $2.9 million for the comparable period in 2015 and a
      reduction in stock compensation expense of $955,000 in the first quarter
      ended March 31, 2016 compared to the corresponding period in 2015.
    </p>
    <p style="text-align: left">
      After adjusting for the non-cash impact of the revaluation of the
      derivative warrant liability, the net loss from operations for the first
      quarter ended March 31, 2016 was $4.9 million compared to $5.7 million
      for the corresponding period in 2015.
    </p>
    <p style="text-align: left">
      The Company incurred net research and development expenditures of $3.3
      million for the first quarter ended March 31, 2016, as compared to $3.3
      million for the same period in 2015. Research and development
      expenditures for both periods related primarily to drug distribution,
      patient enrollment and treatment activities associated with the AURA
      trial.
    </p>
    <p style="text-align: left">
      The Company incurred corporate, administration and business development
      costs of $1.2 million for the first quarter ended March 31, 2016, as
      compared with $1.9 million for the same period in 2015. These costs
      included a non-cash stock compensation expense of $261,000 in 2016
      compared to $897,000 in 2015.
    </p>
    <p style="text-align: left">
      The Company had cash, cash equivalents and short term investments of
      $10.5 million as at March 31, 2016 compared to $15.8 million as at
      December 31, 2015. In order to complete the AURA LN clinical trial and
      be able to undertake further development of voclosporin, the Company
      will need to raise additional funds within the next 12 months.
    </p>
    <p style="text-align: left">
      The unaudited interim condensed consolidated financial statements and
      the MD&amp;A for the first quarter ended March 31, 2016 are accessible on
      Aurinia's website at <u>www.auriniapharma.com</u> or on SEDAR at <u>www.sedar.com</u>
      or on EDGAR at <u>www.sec.gov/edgar</u>.
    </p>
    <p style="text-align: left">
      <sup>1</sup>Dall&#8217;Era, M., Stone, D., Levesque, V., Cisternas,M., &amp;
      Wofsy, D. (2011).<i>Arthritis Care and Research</i>, <i>63</i>(3),
      351&#8211;357.
    </p>
    <p style="text-align: left">
      <i><b>About Aurinia:</b></i>
    </p>
    <p style="text-align: left">
      Aurinia is a clinical stage pharmaceutical company focused on the global
      nephrology market. The fully-enrolled AURA clinical trial is evaluating
      the efficacy of its lead drug, voclosporin, as a treatment for active
      LN. LN is an inflammation of the kidneys, that if inadequately treated
      can lead to end-stage renal disease, making LN a serious and potentially
      life-threatening condition.
    </p>
    <p style="text-align: left">
      Voclosporin is a novel and potentially best-in-class calcineurin
      inhibitor (&#8220;CNI&#8221;) with extensive clinical data in over 2,000 patients in
      other indications. Voclosporin is made by a modification of a single
      amino acid of the cyclosporine molecule (a CNI approved for use in
      transplant patients since 1983). This modification results in a more
      predictable pharmacokinetic and pharmacodynamic relationship, an
      increase in potency vs. cyclosporine, an altered metabolic profile, and
      potential for flat dosing.
    </p>
    <p style="text-align: left">
      <i><b>About AURA:</b></i>
    </p>
    <p style="text-align: left">
      The AURA trial is an adequate and well-controlled clinical trial that
      enrolled 265 patients and is being conducted in over 20 countries
      worldwide. This trial will compare the efficacy of voclosporin against
      placebo in achieving remission in patients with active lupus nephritis.
      The AURA trial designed to demonstrate that voclosporin can induce a
      rapid and sustained reduction of proteinuria in the presence of
      extremely low steroid exposure. It will compare two dosage groups of
      voclosporin (23.7mg and 39.5mg) compared to placebo, with all patients
      receiving mycophenolate mofetil (MMF) and oral corticosteroids as
      background therapy. There will be a primary analysis to determine
      complete remission at week 24 (confirmed at 26 weeks) and various
      secondary analyses at week 48 which include biomarkers and markers of
      non-renal SLE.
    </p>
    <p style="text-align: left">
      <i><b>About AURION:</b></i>
    </p>
    <p style="text-align: left">
      The AURION study is an open label, exploratory study being conducted at
      two sites in Malaysia to assess the short term predictors of response
      using voclosporin (23.7mg) in combination with mycophenolate mofetil and
      oral corticosteroids in patients with active lupus nephritis. This study
      will examine biomarkers of disease activity at 8 weeks and their ability
      to predict response at 24 and 48 weeks.
    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; width: 100%; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: left">
      <i><b>Forward-Looking Statements</b></i>
    </p>
    <p style="text-align: left">
      A statement is forward-looking when it uses what the Company knows and
      expects today to make a statement about the future. Forward-looking
      statements may include words such as &#8220;<i>anticipate&#8221;, &#8220;believe&#8221;,
      &#8220;intend&#8221;, &#8220;expect&#8221;, &#8220;goal&#8221;, &#8220;may&#8221;, &#8220;outlook&#8221;, &#8220;plan&#8221;, &#8220;seek&#8221;, &#8220;should&#8221;,
      &#8220;strive&#8221;, &#8220;target&#8221;, &#8220;could&#8221;, &#8220;continue&#8221;, &#8220;potential&#8221; </i>and
      <i>&#8220;estimated&#8221;</i>, or the negative of such terms or
      comparable terminology. You should not place undue reliance on
      forward-looking statements, particularly those concerning anticipated
      events relating to the development, clinical trials, regulatory
      approval, and marketing of the Company&#8217;s product and the timing or
      magnitude of those events, as they are inherently risky and uncertain.
    </p>
    <p style="text-align: left">
      Securities laws encourage companies to disclose forward-looking
      information so that investors can get a better understanding of the
      Company&#8217;s future prospects and make informed investment decisions. In
      this press release, these statements may include, without limitation:
    </p>
    <ul style="text-align: left">
      <li style="margin-bottom: 10.0px">
        plans to fund the Company&#8217;s operations;
      </li>
      <li style="margin-bottom: 10.0px">
        summary statements relating to results of the past voclosporin trials
        or plans to advance the development of voclosporin;
      </li>
      <li style="margin-bottom: 10.0px">
        the timing of the release of the primary end-point results of AURA ;
      </li>
      <li style="margin-bottom: 10.0px">
        the timing of the analysis and review of the AURA data with the FDA;
      </li>
      <li style="margin-bottom: 10.0px">
        the timing of commencement and completion of clinical trials;
      </li>
      <li style="margin-bottom: 10.0px">
        voclosporin being a best-in-class calcineurin inhibitor;
      </li>
      <li style="margin-bottom: 10.0px">
        the Company&#8217;s anticipated future financial position, future revenues
        and projected costs;
      </li>
      <li style="margin-bottom: 10.0px">
        the Company&#8217;s intention to raise additional funds in the next 12
        months;
      </li>
      <li style="margin-bottom: 10.0px">
        the timing of the Company&#8217;s anticipated milestones for 2016; and
      </li>
      <li style="margin-bottom: 10.0px">
        plans and objectives of management.
      </li>
    </ul>
    <p style="text-align: left">
      Such statements reflect the Company&#8217;s current views with respect to
      future events and are subject to risks and uncertainties and are
      necessarily based on a number of estimates and assumptions that, while
      considered reasonable by the Company, as at the date of such statements,
      are inherently subject to significant business, economic, competitive,
      political, scientific and social uncertainties and contingencies, many
      of which, with respect to future events, are subject to change. The
      factors and assumptions used by the Company to develop such
      forward-looking statements include, but are not limited to: the
      assumption that the Company will be able to reach agreements with
      regulatory agencies on executable development programs; the assumption
      that recruitment to clinical trials will occur as projected; the
      assumption that the Company will successfully complete its clinical
      programs on a timely basis, including the AURA clinical trial currently
      in progress, to enable the Company to proceed to conduct future required
      LN clinical trials and meet regulatory requirements for approval of
      marketing authorization applications and new drug approvals; the
      assumption the regulatory requirements will be maintained; the
      assumption that the Company will be able to manufacture and secure a
      sufficient supply of voclosporin on a timely basis to successfully
      complete the development and commercialization of voclosporin; the
      assumption that market data and reports reviewed by the Company are
      accurate; the assumptions relating to the availability of capital on
      terms that are favourable to the Company; the assumption that the
      Company will be able to attract and retain skilled staff; the assumption
      that general business and economic conditions will be maintained, and
      the assumptions relating to the feasibility of future clinical trials.
    </p>
    <p style="text-align: left">
      It is important to know that:
    </p>
    <ul style="text-align: left">
      <li style="margin-bottom: 10.0px">
        Actual results could be materially different from what the Company
        expects if known or unknown risks affect its business, or if the
        Company&#8217;s estimates or assumptions turn out to be inaccurate. As a
        result, the Company cannot guarantee that any forward-looking
        statement will materialize and, accordingly, you are cautioned not to
        place undue reliance on these forward-looking statements.
      </li>
      <li style="margin-bottom: 10.0px">
        Forward-looking statements do not take into account the effect that
        transactions or non-recurring or other special items announced or
        occurring after the statements are made may have on the Company&#8217;s
        business. For example, they do not include the effect of mergers,
        acquisitions, other business combinations or transactions,
        dispositions, sales of assets, asset write-downs or other charges
        announced or occurring after the forward-looking statements are made.
        The financial impact of such transactions and non-recurring and other
        special items can be complex and necessarily depends on the facts
        particular to each of them. Accordingly, the expected impact cannot be
        meaningfully described in the abstract or presented in the same manner
        as known risks affecting the Company&#8217;s business.
      </li>
      <li style="margin-bottom: 10.0px">
        The Company disclaims any intention and assumes no obligation to
        update any forward-looking statements even if new information becomes
        available, as a result of future events, new information, or for any
        other reason except as required by law.
      </li>
    </ul>
    <p style="text-align: left">
      Such forward-looking statements involve known and unknown risks,
      uncertainties, and other factors that may cause the Company&#8217;s actual
      results, performance, or achievements to differ materially from any
      further results, performance or achievements expressed or implied by
      such forward-looking statements. Important factors that could cause such
      differences include, among other things, the following:
    </p>
    <ul style="text-align: left">
      <li style="margin-bottom: 10.0px">
        the need for additional capital to fund the Company&#8217;s development
        programs and the effect of capital market conditions and other factors
        on capital availability;
      </li>
      <li style="margin-bottom: 10.0px">
        difficulties, delays, or failures the Company may experience in the
        conduct of and reporting of results of its clinical trials for
        voclosporin, and in particular its current AURA clinical trial;
      </li>
      <li style="margin-bottom: 10.0px">
        difficulties, delays or failures in obtaining regulatory approvals for
        the initiation of clinical trials;
      </li>
      <li style="margin-bottom: 10.0px">
        difficulties the Company may experience in completing the development
        and commercialization of voclosporin;
      </li>
    </ul>
    <p style="text-align: left">
      Although the Company believes that the expectations reflected in the
      forward-looking statements are reasonable, the Company cannot guarantee
      future results, levels of activity, performance or achievements. These
      forward-looking statements are made as of the date hereof.
    </p>
    <p style="text-align: left">
      <i>We seek Safe Harbor</i>.
    </p>
    <p style="text-align: left">

    </p>
    <p>
      CONTACT:<br>
    </p>
    <p style="text-align: left">
      Aurinia Pharmaceuticals Inc.<br>Mr. Michael Martin, 250-708-4272<br>Chief
      Operating Officer<br>Fax: (250) 744-2498<br>mmartin@auriniapharma.com<br>or<br>Mr.
      Dennis Bourgeault, 780-643-2260<br>Chief Financial Officer<br>Aurinia
      Pharmaceuticals Inc.<br>Fax: 780-484-4105<br><u>dbourgeault@auriniapharma.com</u>
    </p>
    <p style="text-align: left">

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
